secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ainos, Inc. (AIMD)
CIK:        0001014763
Form:       8-K
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0001493152-25-009578
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ainos reports FY2024 revenue $20,729, net loss $14.9M; AI Nose and VELDONA progress
--------------------------------------------------------------------------------

- Revenue fell 83% YoY to $20,729; cost of revenues $52,595; gross loss narrowed to $31,866.
- Net loss attributable to common shareholders $14.86M vs $13.77M in FY2023.
- Cash and equivalents $3.89M as of Dec 31, 2024, up from $1.89M a year ago.
- R&D expenses rose to $8.4M (including share-based comp); SG&A decreased to $5.4M.
- Key milestones: AI Nose Flora second-gen clinical studies H1 2025; VELDONA Japan patent and Taiwan Tanabe partnership; IRB approval for Sjögren's trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1014763/000149315225009578/0001493152-25-009578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1014763/000149315225009578/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer